combined oral contraceptives for PCOS
A single study reports that combined oral contraceptives effectively reduce circulating androgens in women with PCOS.
Hypothesized mechanism
Combined oral contraceptives suppress ovarian androgen production and likely increase SHBG, lowering circulating androgen levels.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 5 of 10 overall, a emerging reading, from a direct rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
Only a single source is cited (a study on Low Dose OC Therapy in Women With PCOS). There is no independent replication, and the single primary study scores 0 for corroboration.
Rigor
The source appears to be a single clinical study examining low-dose OC therapy and BMI impact, with no indication of being an RCT or meta-analysis. This represents observational/small trial level evidence, scoring 1.
Specificity
The claim directly names both the intervention (combined oral contraceptives) and the condition (PCOS), explicitly studying OCs 'in women with PCOS.'
Plausibility
The claim asserts that OCs reduce circulating androgens, a mechanistically plausible effect (suppression of ovarian androgen production and increased SHBG), but the quote states the effect without detailing the mechanism, so it is plausible rather than directly evidenced.
Consistency
Only a single claim from a single source is provided, so directional consistency across studies cannot be assessed; per the n/a rule this is scored 1.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1combined oral contraceptives (OCs) in women with PCOS effectively reduces circulating androgens ClinicalTrials.gov · NCT01360996 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →